PE20010316A1 - GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES - Google Patents
GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USESInfo
- Publication number
- PE20010316A1 PE20010316A1 PE2000000446A PE0004462000A PE20010316A1 PE 20010316 A1 PE20010316 A1 PE 20010316A1 PE 2000000446 A PE2000000446 A PE 2000000446A PE 0004462000 A PE0004462000 A PE 0004462000A PE 20010316 A1 PE20010316 A1 PE 20010316A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- intracellularis
- lawsonia
- refers
- sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 241001469654 Lawsonia <weevil> Species 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 241001148567 Lawsonia intracellularis Species 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000037029 cross reaction Effects 0.000 abstract 1
- 239000003228 hemolysin Substances 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO INMUNOGENICO AISLADO O RECOMBINANTE CARACTERIZADO PORQUE TIENE UNA REACCION CRUZADA CON UN EPITOPE DE CELULA B O CELULA T DE UN POLIPEPTIDO LAWSONIA SPP FlgE DE PREFERENCIA L. INTRACELLULARIS, SE CARACTERIZA POR PROVOCAR LA PRODUCCION DE ANTICUERPOS, CONFERIR UNA RESPUESTA INMUNOLOGICA PROTECTORA EN UN ANIMAL, PORCINO, AVE; INDUCIR INMUNIDAD HUMORAL; ES SELECCIONADO DE: a)UN PEPTIDO, OLIGOPEPTIDO, POLIPEPTIDO QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS 60% DE IDENTIDAD DE LA SECUENCIA No ID SEC:1 DE 502 AMINOACIDOS O LA SECUENCIA DE AMINOACIDOS CODIFICADA POR LA SECUENCIA DE NUCLEOTIDOS QUE CODIFICA FlgE DE pALK11 (ATCC 207156); b)UN HOMOLOGO, ANALOGO, DERIVADO QUE IMITA A UN EPITOPE DE CELULA B O T DE UN POLIPEPTIDO DE LAWSONIA SPP. SE REFIERE TAMBIEN A UNA VACUNA QUE COMPRENDE ADEMAS OTRO COMPONENTE INMUNOGENICO QUE COMPRENDE UN PEPTIDO O PROTEINA DE L. INTRACELLULARIS ANTIGENICA DE PREFERENCIA OmPh, SodC, HEMOLISINA, AUTOLISINA; TAMBIEN SE REFIERE A UN VECTOR QUE COMPRENDE UN ACIDO NUCLEICO CON UNA SECUENCIA QUE CODIFICA AL POLIPEPTIDO; UN ACIDO NUCLEICO AISLADO QUE CODIFICA AL POLIPEPTIDO; UN PLASMIDO pALK11. EL POLIPEPTIDO CODIFICADO DE UN GEN DERIVADO DE LAWSONIA PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDAD INTESTINAL EN ANIMALES Y PAJAROSIT REFERS TO AN ISOLATED OR RECOMBINANT IMMUNOGENIC POLYPEPTIDE CHARACTERIZED BECAUSE IT HAS A CROSS-REACTION WITH AN EPITO CELL B OR CELL T OF A LAWSONIA SPP FlgE POLYPEPTIDE OF PREFERENCE L. INTRACELLULARIS PROVIDES AN INTRACELLULARIS PROVIDED FOR AN INTRACELLULARIS PROVIDED PROTECTION. AN ANIMAL, PORCINE, AVE; INDUCE HUMORAL IMMUNITY; IT IS SELECTED FROM: a) A PEPTIDE, OLIGOPEPTIDE, POLYPEPTIDE THAT COMPRISES A SEQUENCE OF AMINO ACIDS THAT HAS AT LEAST 60% IDENTITY OF THE SEQUENCE NO. PALK11 FlgE (ATCC 207156); b) A HOMOLOGICAL, ANALOGUE, DERIVATIVE THAT IMITATES A B OR T CELL EPITOPE OF A LAWSONIA SPP POLYPEPTIDE. IT ALSO REFERS TO A VACCINE THAT ALSO INCLUDES ANOTHER IMMUNOGENIC COMPONENT INCLUDING A PEPTIDE OR PROTEIN OF THE ANTIGENIC L. INTRACELLULARIS OF PREFERENCE OmPh, SodC, HEMOLYSIN, AUTOLYSIN; IT ALSO REFERS TO A VECTOR THAT INCLUDES A NUCLEIC ACID WITH A SEQUENCE THAT ENCODES THE POLYPEPTIDE; AN ISOLATED NUCLEIC ACID THAT ENCODES POLYPEPTIDE; A PLASMID pALK11. THE POLYPEPTIDE CODED FROM A LAWSONIA DERIVED GENE MAY BE USEFUL FOR THE TREATMENT OF INTESTINAL DISEASE IN ANIMALS AND BIRDS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13397399P | 1999-05-13 | 1999-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010316A1 true PE20010316A1 (en) | 2001-03-15 |
Family
ID=22461178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000446A PE20010316A1 (en) | 1999-05-13 | 2000-05-12 | GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1181315A4 (en) |
| JP (1) | JP2003516113A (en) |
| AU (1) | AU771376B2 (en) |
| BR (1) | BR0011294A (en) |
| CA (1) | CA2372098A1 (en) |
| MX (1) | MXPA01011669A (en) |
| NZ (1) | NZ515331A (en) |
| PE (1) | PE20010316A1 (en) |
| WO (1) | WO2000069904A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605696B1 (en) | 1999-10-22 | 2003-08-12 | Pfizer, Inc. | Lawsonia intracellularis proteins, and related methods and materials |
| DE60144201D1 (en) | 2000-12-20 | 2011-04-21 | Intervet Int Bv | Lawsonia intracellular vaccine |
| ATE450545T1 (en) * | 2003-09-12 | 2009-12-15 | Intervet Int Bv | LAWSONIA INTRACELLULARIS SUBUNIT VACCINE |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| US8398994B2 (en) | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
| US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| CN114712392B (en) * | 2022-05-16 | 2022-11-25 | 西部医美生物科技成都有限公司双流医疗分公司 | Immune cell preparation from autologous blood separation and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885823A (en) * | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
| CN1145697C (en) * | 1995-11-30 | 2004-04-14 | 维多利亚农业服务控股公司 | Therapeutic and diagnostic compositions |
-
2000
- 2000-05-11 JP JP2000618320A patent/JP2003516113A/en active Pending
- 2000-05-11 AU AU43859/00A patent/AU771376B2/en not_active Ceased
- 2000-05-11 EP EP00924976A patent/EP1181315A4/en not_active Withdrawn
- 2000-05-11 WO PCT/AU2000/000437 patent/WO2000069904A1/en not_active Application Discontinuation
- 2000-05-11 BR BR0011294-1A patent/BR0011294A/en not_active IP Right Cessation
- 2000-05-11 MX MXPA01011669A patent/MXPA01011669A/en unknown
- 2000-05-11 NZ NZ515331A patent/NZ515331A/en unknown
- 2000-05-11 CA CA002372098A patent/CA2372098A1/en not_active Abandoned
- 2000-05-12 PE PE2000000446A patent/PE20010316A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU771376B2 (en) | 2004-03-18 |
| AU4385900A (en) | 2000-12-05 |
| EP1181315A1 (en) | 2002-02-27 |
| BR0011294A (en) | 2002-02-26 |
| NZ515331A (en) | 2003-07-25 |
| MXPA01011669A (en) | 2003-09-10 |
| CA2372098A1 (en) | 2000-11-23 |
| JP2003516113A (en) | 2003-05-13 |
| WO2000069904A1 (en) | 2000-11-23 |
| EP1181315A4 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9711090A (en) | Isolated omp106 polypeptide or substantially pure antibody isolated peptide fragment of the omp106 polypeptide vaccine antigenic composition dna substantially pure process for producing an immune response in an animal and process for producing a non-hemagglutinating cultivar of m catarrhalis from a strain or cultivar of m catarrhalis ha | |
| ATE319091T1 (en) | DIAGNOSIS OF NATIVE SPRUE/CELIAC DISEASE USING GLIADINE PITOPES | |
| AR018603A1 (en) | A PEPTIDE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF ALZHEIMER'S DISEASE AND THE DOWN SYNDROME, PHARMACEUTICAL COMPOSITIONS AND VACCINES WHICH LOCATE, THE USE OF SUCH PEPTIDE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS OF DNA, SECTION A PLASMID OR VECTOR VI | |
| DE60332645D1 (en) | II-KEY / ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINE | |
| BR0010720A (en) | Antigenic neisseria peptides | |
| BRPI0412799A (en) | immunogen, composition, nucleic acid, recombinant cell, methods for preparing a polypeptide, for inducing a protective immune response in a patient and for inducing an anamnesic response in a patient, and optimized yeast nucleic acid sequence | |
| DE69129865D1 (en) | OSTEOGENEIC PEPTIDES | |
| DE69733773D1 (en) | Fas ANTIGEN DERIVATIVES | |
| PE20010316A1 (en) | GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | |
| BR9710975A (en) | Genes of 120 kda exposed surface adhesion protein immunodominant of ehrlichia chaffeensis | |
| ATE154638T1 (en) | MUTANTS OF INTERLEUKIN-3 | |
| WO2002008716A3 (en) | Method for screening peptides for use in immunotherapy | |
| BR0309491A (en) | Vaccine composition, immunogenic composition, use of an e7 protein and neutralizing antibodies | |
| PE20010237A1 (en) | GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES | |
| PE20010238A1 (en) | GENE DERIVED FROM LAWSONIA AND POLYPEPTIDES SodC, PEPTIDES AND RELATED PROTEINS AND THEIR USES | |
| AU6961601A (en) | Transport peptides among which c-terminal E<sup>rns</sup> peptide and analogues thereof | |
| PE20010239A1 (en) | GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS OF HEMOLYSIN AND THEIR USES | |
| NZ507983A (en) | A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof | |
| WO2002044202A3 (en) | Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof | |
| NO20011263D0 (en) | Moraxella Catarrhalis BASBO34 polypeptides and uses thereof | |
| WO1998040497A3 (en) | An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method | |
| WO2003064446A3 (en) | Plasma protein-binding peptides from bacterial curli | |
| DE69130675T2 (en) | CLONING AND EXPRESSION OF A RHOPTRY-ASSOCIATED PROTEIN FROM P. FALCIPARUM | |
| Gao et al. | Structure‐activity relationships of sialogogic heptapeptides analogous to physalaemin | |
| AR004191A1 (en) | POLYPEPTIDES TO INDUCE PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS, DNA MOLECULES THAT CODES THEM, A VECTOR OF EXPRESSION, A HOST CELL, A VACCINE, A FUSION PROTEIN, A METHOD OF DETECTING TUBERCULOSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |